AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
HANGZHOU, China, June 06, 2021 (GLOBE NEWSWIRE) — AnHeart Therapeutics Co., Ltd (AnHeart), a clinical stage oncology company focused on underserved patients in global markets, together with Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announce a presentation of a scientific poster entitled Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer (NSCLC) which summarizes initial…
